All In Biotech

Drug Trial Radar · NCT06264310

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

A Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Combined With Standard of Care Versus Standard of Care Alone in Outpatients With Worsening Heart Failure (WHF)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Mar 1, 2024

Primary completion

Nov 4, 2024

Study completion Nov 25, 2024

Sponsor

Lead sponsor
River 2 Renal Corp.Industry
Sponsor type
Industry
Collaborators
International HealthCare, LLC
First posted
Feb 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Conditions

  • Heart Failure
  • Worsening Heart Failure (WHF)

Interventions

  • PlaceboDrug

    Matching placebo SC injection

  • R2R01Drug

    Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.Time frame: Day 7, Day 30
  2. Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0.Time frame: Day 30

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Thomas Hospital

    Fairhope, Alabama

  • C&R Research

    Fort Meyers, Florida

  • C&R Research

    Hialeah, Florida

  • Encore Clinical Research

    Inverness, Florida

  • Encore Clinical Research

    Jacksonville, Florida

  • Amavita Clinical Research

    Miami, Florida

  • Lake Country

    Eatonton, Georgia

  • J&S Studies

    College Station, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.